Update in the Diagnosis and Treatment of Mycoplasma Pneumoniae Pneumonia in Children
International Journal of Stem Cells and Medicine · 2026
DOI: 10.58489/2836-5038/025 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Stem Cells and Medicine, 2026. Verfasst von Wenyan Wang und 9 weiteren Autor:innen.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
This paper analyzes and studies the diagnosis and treatment of Mycoplasma pneumoniae pneumonia (MPP) by referring to relevant domestic and international literature, aiming to provide new methods and references for the clinical diagnosis of MPP in children. Mycoplasma pneumoniae pneumonia (MPP) is a common community-acquired pneumonia in pediatrics, a lower respiratory tract infection caused by Mycoplasma pneumoniae. Mycoplasma pneumoniae is a unique microorganism capable of growing and reproducing in cell-free culture media. It primarily attacks the human respiratory tract and lungs, and in severe cases, can affect multiple organs throughout the body. Its clinical manifestations are diverse, ranging from mild self-limiting cases to severe pneumonia or extrapulmonary complications. Timely and accurate diagnosis is crucial for treatment. Traditional methods such as serological antibody detection, while widely used, still have limitations, including a diagnostic "window period" and delayed results. Molecular diagnostic methods centered on nucleic acid detection technology, such as real-time fluorescent PCR, have become a core tool for early clinical diagnosis due to their rapidity and high sensitivity. Additionally, direct antigen detection, biomarkers for assessing disease severity and prognosis, and imaging examinations like high-resolution CT collectively form a more comprehensive and multi-dimensional diagnostic system. Referring to domestic and international literature on MPP, this paper analyzes and studies its diagnosis and treatment. It is anticipated that future developments in diagnostic technology will focus more on the popularization of rapid point-of-care testing and the deepening of artificial intelligence-assisted analysis. The aim is to provide new methods and references for the clinical diagnosis of MPP in children, thereby comprehensively improving the diagnostic and therapeu tic standards for pediatric MPP.
Zitieren
APA
Wang, W., Li, J., Gao, D., Zhang, J., Hu, J., Gao, H., Shi, B., Shi, X., Yang, X., & Zi, H. (2026). Update in the Diagnosis and Treatment of Mycoplasma Pneumoniae Pneumonia in Children. International Journal of Stem Cells and Medicine. https://doi.org/10.58489/2836-5038/025
Vancouver
Wang W, Li J, Gao D, Zhang J, Hu J, Gao H, et al. Update in the Diagnosis and Treatment of Mycoplasma Pneumoniae Pneumonia in Children. International Journal of Stem Cells and Medicine. 2026. doi:10.58489/2836-5038/025
BibTeX
@article{Wang2026,
author = {Wang, Wenyan and Li, Jiayi and Gao, Diaoyan and Zhang, Jingwen and Hu, Jingxue and Gao, Huizhen and Shi, Beibei and Shi, Xiaoxiao and Yang, Xiaorong and Zi, Heping},
title = {Update in the Diagnosis and Treatment of Mycoplasma Pneumoniae Pneumonia in Children},
journal = {International Journal of Stem Cells and Medicine},
year = {2026},
doi = {10.58489/2836-5038/025}
}
EUVIMED